Yüklüyor......
Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases
JAK-2 dysregulation plays an important role as an oncogenic driver, and is thus a promising therapeutic target in hematological malignancies. Ruxolitinib is a pyrrolo[2.3-d]pyrimidine derivative with inhibitory activity against JAK1 and JAK2, moderate activity against TYK2, and minor activity agains...
Kaydedildi:
| Yayımlandı: | Oncotarget |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Impact Journals LLC
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5732767/ https://ncbi.nlm.nih.gov/pubmed/29262601 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.21951 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|